Forte Medical joins ABHI UK Healthcare Pavilion

The Association of British HealthTech Industries (ABHI) recently launched the UK Healthcare Pavilion, a single platform to unite MedTech companies with the UK healthcare sectors, both NHS and private. Forte Medical is very happy to have joined such an august and respected portfolio of companies, providers and innovators.  Our entry features films about our technology featuring advocates, policy makers, healthcare professionals and the AHSN Network. Click here to view.

Antibiotics and urinary tract infections

Antibiotics, better tests, UTI: Guardian publishes Forte response

A rise in persistent UTIs could be linked to antibiotic crackdown appeared in The Guardian on Saturday 5th October. As usual, no-one mentioned accurate basic specimen collection, which can lead to unwarranted specimen quality variation, failed analysis and less-than-targeted prescribing. Giovanna Forte had something to say. Click here to read her published letter.

Forte Medical Review

A Year In Review – 2018

  • New evidence showing a 70% reduction in false positive dipped specimens
  • Extended uptake by the NHS
  • Investment including a JV to create a Smart Peezy
  • Sheena Byrom joining our Advisory Panel
  • Being recognised in the Sunday Times 2018 Maserati 100 list that celebrate British entrepreneurship

These have been a few of our highlights for 2018 – to read more, please click here

Misdiagnosis of urine samples

Mr Ased Ali – Making Urine Samples Trustworthy

The latest issue of Urology News features an interesting and important conversation with Urological Consultant Mr Ased Ali about the importance of urine in diagnosis and subsequent treatment of UTIs.  He refers to the patient-led initiative – the MUST Campaign – that is demanding Government introduce a protocol for the collection of urine specimens.

The article supports the work being undertaken – the petition can be signed here – and the article itself is on page 35 of the November/December issue.

Clinical research using the Peezy Midstream shows a 70% reduction in false positive dipped urines and mixed growth/contamination reduced from the national average of 22.5% to just 2%.  Our contribution to making urine samples trustworthy

Urine infections

Knowledge of Men’s Health Dangerously Low

Amongst British adults, urology diseases such as testicular cancer and prostate cancer are not well understood and men are not looking out for the signs and symptoms of these deadly diseases.

This was the revealing and shocking research undertaken as part of Urology Awareness Month that was presented at our Forum last month by The Urology Foundation’s CEO, Louise de Winter.

  • 70% of British adults do not know the correct age from which men should be tested for prostate cancer
  • 2 in 3 British adults do not know what a prostate does
  • More than half of British adults do not know the age range when men are most likely to get testicular cancer
  • Half of British men have not checked their testicles for lumps in the last year (doctors recommend once a month)

 

Read here for more information from The Urology Foundation.

Peezy Usability Study Forte Medical

Peezy Midstream Case Study at NHS NIHR Conference 2018

Back in March of this year, the NHS National Institute for Health Research contacted Forte Medical, asking for a case study demonstrating how their research has assisted the launch of Peezy Midstream.

A few months earlier the NIHR in conjunction with the West Midlands AHSN conducted a valuable Usability Study on our diagnostic device. Results were excellent and have assisted us with adoption training and reassurance to HCPs and patients alike that using Peezy Midstream is far, far easier than trying to deliver this elusive urine specimen any other way …

The case study presented by Giovanna Forte on 10th October 2018 was very well received and has already led to enquiries from Primary Care clinicians who can see the benefit of right-first-time diagnoses for UTI and other common conditions that can take up so much GP time when left untreated.

2018 NIHR Peezy Presentation

NIHR_PeezyMidstream-Case-Study

Forte Medical: Series A investment growth round is open

This week saw the launch of Forte Medical’s Series A investment round for growth, export and new product development. Seeking £3.5m, the company is engaging with prospective investment partners who can attract investors with an interest in evidenced, disruptive diagnostic medical devices with digital potential.

Institutional, corporate or personal investors who can assist the business long term are seen as the most promising and attractive partners. For more information, contact our CEO Giovanna Forte.

Giovanna Forte on TV

Disruptive TV: Giant Live Health Innovators

Barry Shrier, Founder of annual health innovation event Giant Live, presents the third Disruptor Giant Health Innovators TV interview featuring Giovanna Forte, CEO of Forte Medical, Francis White from AliveCor, Dr Sophie Bostoc​k of Sleepio and Etienne Bourdon from Healthy Health. Watch the half-hour programme here with Disruptive Live

Urine sample collection

Trends in Urology & Men’s Health: solving the problem of contaminated urine samples

Despite its importance, there is no standard for urine collection. In this article the author, Professor Frank Chinegwundoh, discusses the problem of inadequate samples and describes a collection system that can help. Visit the Jan-Feb issue of Trends in Urology & Men’s Health.

New Forte Medical Advisory Board

Encouraged by the growing national recognition of the value of urine in diagnostic medicine, health leaders are being approached to join a new Forte Medical Advisory Board. Three leading exponents of accurate basic medicine have so far been appointed: Mike Farrar (pic) who will Chair the panel, Dr Katherine Brown and Rachel Cashman

Mike Farrar is a management consultant with 15 years of CEO experience in the NHS, having stepped down as the Chief Executive of the NHS Confederation in September 2013.  Mike has been a member of the PwC Health Industries Oversight Board and has worked on major projects across the country. Mike has also built alongside this a successful business practice working with clients such as Celesio, ROGP, ABPI, NHS Quest, NHS Leadership Academy, Health Foundation, Vanguard Health Solutions, Pfizer, CIPFA and others, as well as starting up a number of small companies aimed at promoting health innovations, and links between health and sport.

He has been Chief Executive of North West England SHA, West Yorkshire, and South Yorkshire Strategic Health Authorities and Tees Valley Health Authority and Head of Primary Care at the Department of Health. Mike remains a prominent thought leader and consultant to the NHS throughout the UK

Dr Katherine Brown is an academic based in the UK and the US with over 100 peer-reviewed publications.  She is affiliated with Cambridge and Imperial Universities and the University of Texas. With over 25 years in medical applications, she has extensive expertise in biochemistry, biophysics, infectious disease and bio/nanotechnology.

Rachel Cashman is Managing Director, The Soircas Consultancy and former Head of Clinical and Scientific Policy and Strategy, NHS England

During her 20+ years in the healthcare and life sciences sectors, Rachel has delivered large-scale change and innovation through inter-sectoral collaboration and the development of networks. At NHS England, she led the establishment of Academic Health Science Networks (AHSNs) and the process to create the first nationally commissioned network of Genomic Medicine Centres, utilising the latest scientific techniques in understanding human DNA in order to better predict, precisely diagnose and personalise treatment of cancers and rare disease.

She has worked with NHS Trusts and CCGs and their local health and care system partners to develop appropriate governance and infrastructure in response to the NHS Five Year Forward View and the emergence of the Sustainability and Transformation Partnerships. As a Board member at University Hospitals Birmingham NHS Foundation Trust and Heart of England NHS Trust, Rachel designed the strategic business case and engagement process for the proposed merger. Rachel has played an integral role in helping the NHS utilise rapid assessment protocols to evaluate potential partnership opportunities such as hospital chains, franchise models, mergers, accountable care organisations and multi-specialty community provider organisations.